Both chronic and acute administration of LPS in animal models mimics the pathological hallmarks of diabetic retinopathy (DR) or exacerbates existing retinopathy in diabetes by targeting Toll-like receptor 4 (TLR4) [6, 7]. The gene discussed is TLR4; the disease is diabetic retinopathy.